ImmuPharma (LON:IMM) Stock Price Up 28.8% – Here’s What Happened

ImmuPharma plc (LON:IMMGet Free Report)’s share price rose 28.8% during trading on Saturday . The stock traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares were traded during mid-day trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Price Performance

The company has a 50-day moving average price of GBX 3.12 and a 200 day moving average price of GBX 2.91. The firm has a market capitalization of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMMGet Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Recommended Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.